Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs 985

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 985 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Pipeline programs

Page 8 of 21

  1. Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  3. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

  4. WN43174

    Hoffmann-La Roche

    NMDAR or LGI1 mediated autoimmune Encephalitis

    phase 3 other active

    1 trial

  5. Wobenzym® N

    Atrium Therapeutics

    Knee Osteoarthritis

    phase 3 other terminated

    1 trial

  6. ZASOCITINIB

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  7. ZILRETTA

    Pacira Ireland Limited

    Glenohumeral Osteoarthritis

    phase 3 small molecule active

    1 trial

  8. Zasocitinib

    Takeda

    Plaque Psoriasis

    phase 3 small molecule active

    2 trials

  9. Zasocitinib

    Takeda

    Psoriatic Arthritis

    phase 3 small molecule active

    3 trials

  10. Zilucoplan sodium

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  11. bimekizumab

    Lacuna Pharma Pty Ltd

    Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  12. bimekizumab

    Lacuna Pharma Pty Ltd

    Axial Spondyloarthritis

    phase 3 small molecule active

    1 trial

  13. bimekizumab

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  14. blisibimod

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  15. bupivacaine liposome injectable suspension

    Pacira Ireland Limited

    Knee Osteoarthritis

    phase 3 small molecule completed

    1 trial

  16. dehydroepiandrosterone

    Ultragenyx UK Limited

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    3 trials

  17. hydroxychloroquine (Z0188)

    Sanofi Pasteur

    Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  18. ianalumab

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  19. ianalumab s.c. q4w

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule active

    1 trial

  20. mesalazine (Asacol®)

    Cardiff Oncology

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  21. mycophenolate mofetil (CellCept)

    Hoffmann-La Roche

    Myasthenia Gravis, Generalized

    phase 3 small molecule completed

    1 trial

  22. piclidenoson

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  23. placebo for risankizumab

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  24. placebo for risankizumab IV

    AbbVie

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  25. risankizumab

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  26. risankizumab IV

    AbbVie

    Ulcerative Colitis (UC)

    phase 3 small molecule completed

    1 trial

  27. sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    6 trials

  28. secukinumab

    Novartis Pharmaceuticals

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial

  29. tacrolimus capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lupus Nephritis

    phase 3 small molecule terminated

    1 trial

  30. tocilizumab [RoActemra/Actemra]

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  31. total knee arthroplasty

    Hospital Authority, Hong Kong

    Osteoarthritis, Knee

    phase 3 mab active

    1 trial

  32. voclosporin

    Aurinia Pharmaceuticals

    Psoriasis

    phase 3 small molecule completed

    3 trials

  33. -aminosalicylic acid

    Ultragenyx UK Limited

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  34. 114055

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  35. 1425-0003

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial

  36. 1509-0004

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  37. 200908

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  38. 20170104

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  39. 20210210

    Amgen

    Ulcerative Colitis (UC)

    phase 2 other active

    1 trial

  40. 2022/3418 INDIGO

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  41. 3133003

    Orion Laboratories Pty.

    Chronic Pain due to Ostheoarthritis of the knee

    phase 2 small molecule active

    1 trial

  42. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Axial Spondyloarthritis

    phase 2 small molecule active

    1 trial

  43. 626

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  44. 627

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Ulcerative Colitis (UC)

    phase 2 small molecule active

    1 trial

  45. 68Ga-FAPI-46, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis, axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  46. 75mg SHP647 (PF-00547659)

    Takeda

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  47. 77242113UCO2001

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  48. 78934804CRD2001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

985 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.